Image of spreadsheets on glass table during discussion of strategy

Keryx Biopharm Inc (NASDAQ:KERX) shares traded -0.44% down during most recent session to reach at the closing price of $4.53. The stock exchanged hands 4.87 Million shares versus average trading capacity of 1.29 Million shares, yielding a market cap of $542.2 Million. Wall Street analysts covering the stock are projecting that the stock will reach $6.56 within the next 52-weeks. The mean target projections are based on 8 opinions.

Taking a broader look brokerage firms’ analysts on the street with an expectant view have Keryx Biopharm Inc (NASDAQ:KERX) high price target of $9 and with a conservative view have low price target of $5.

Morgan Stanley “Maintained” Keryx Biopharm Inc (NASDAQ:KERX) in a research note issued to investors on 2/08/18 to Equal-Weight with price target of $6.

Additionally on 11/08/17 Stifel Nicolaus “Maintained” Keryx Biopharm Inc (NASDAQ:KERX) to Hold setting price target at $5 and on 7/25/17 Morgan Stanley “Maintained” the stock to Equal-Weight at $7. Furthermore on 1/11/17 Citigroup “Upgrades” the stock to Neutral at $0.

On the other hand the company has Relative Strength Index (RSI 14) of 40.73 along with Average True Range (ATR 14) of 0.25, Consequently Keryx Biopharm Inc (NASDAQ:KERX)’s weekly and monthly volatility is 6.00%, 4.80% respectively. The company’s beta value is at 2.59.

In terms of Buy, Sell or Hold recommendations, Keryx Biopharm Inc (NASDAQ:KERX) has analysts’ mean recommendation of 2.4. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

According to analysts Keryx Biopharm Inc (NASDAQ:KERX)’s minimum EPS for the current quarter is at $-0.25 and can go high up to $-0.14. The consensus mean EPS for the current quarter is at $-0.18 derived from a total of 9 estimates from the analysts who have weighed in on projected earnings. However the company reported $-0.21 earnings per share for the same quarter during last year.

Previously Keryx Biopharm Inc (NASDAQ:KERX) reported $-0.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $-0.18 by $-0.08. The company posted an earnings surprise of -44.4%.

Keryx Biopharm Inc (NASDAQ:KERX)’s revenue estimates for the current quarter are $21.98 Million according to 5 number of analysts, for the current quarter the company has high revenue estimates of $24.33 Million in contradiction of low revenue estimates of $19 Million. For the current year the company’s revenue estimates are $107.43 Million compared to low analyst estimates of $94.5 Million and high estimates of $114.31 Million according to 8 number of analysts.

Currently Keryx Biopharm Inc (NASDAQ:KERX)’s shares owned by insiders are 0.7%, whereas shares owned by institutional owners are 66.9%. However the six-month change in the insider ownership was recorded -7.03%, as well as three-month change in the institutional ownership was recorded -0.08%.

Keryx Biopharm Inc (NASDAQ:KERX) 52-week high price stands at $8.38 and low price stands at $4.01, its price distance from 52-week high is -45.94% while its distance from 52-week low price is 12.97%. The stock hit its 52-week high on 07/12/17, and 52-week low on 02/07/18.

Keryx Biopharm Inc (NASDAQ:KERX)’s trailing twelve month revenues are $60.6 Million, whereas its price to sales ratio for the same period is 8.95. Its book value per share for the most recent quarter is $-0.12 while its price to book ratio for the same period is 0, as for as the company’s cash per share for the most recent quarter is $0.78, however its price to cash per share ratio for the same period is 5.8. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.